enes

Strategy

G

enera Biotech acts to bridge the gap between technology providers (universities, research centers, hospital foundations and small biotechnology-based companies) and plaintiffs (medium and large pharmaceutical or biotechnology companies and others companies), by to put added value to the technology, making it more attractive in the market.

We look for to identify, evaluate and in-license breakthrough cutting-edge science knowledge and biotechnologies.

The added value is carried out by developing an early-stage R&D (proofs of concepts trials, preclinical and early clinical phases) to facilitate subsequent licensing, sale or launching biotech start-ups. Expected revenues will be distributed, according to prior agreement between investors and the originators of the starting technologies.

The research and development strategy of GB  is build its pipeline through in-licensing and partnerships with scientist experts and its practice of leveraging resources through collaborations lowering risks and costs. Value to shareholders is generated by royalty-bearing licensing agreements.

Since the relationship between the investment and the value generated is very favorable at this early-stage of development, we can carry out more projects and therefore increase the likelihood of success. The results of this early-stage R & D are biotechnological products that are more attractive for large pharmaceutical and biotechnology companies.

Areas of interest

  • Identification of Biomarkers
  • Development of new drug therapies
  • Development kits or genetic tests for personalized medicine or for research use
  • Pharmacogenetics
  • Nanotechnology
  • Functional foods